UnitedHealth CEO: Unknowns of Biogen Alzheimer’s drug mean insurer won’t yet cover it

UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on Aduhelm, Biogen’s controversial Alzheimer’s drug, before it will cover it.

Advertisement

During UnitedHealth’s July 15 earnings conference call, Mr. Witty addressed Aduhelm coverage, noting that while he understands members and their families are hoping for coverage progress, there are too many unknowns.

CMO Richard Migliori, MD, said UnitedHealth will be looking toward experts, professional organizations and physicians for guidance.

“We are continuing to develop our clinical policy as well as our ultimate position on coverage, but in doing so, we’re looking forward to getting the guidance that we need from Medicare, and also looking at the clinical evidence that comes from the ongoing clinical trials,” said Dr. Migliori.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.